Development of AAS 500 mg tablets influenced by direct compression (CD) process
Abstract
The present work aims to show the technologic viability in the development of AAS 500 mg tablets using direct compression (CD) process. We employed Starch 1500® as excipient to develop the formulations, trying to investigate its compression, disintegration, aggregation and lubrication properties. Technologic, physical and chemical essays were performed using methodologies anticipated in pharmacology. Results demonstrated that the powder mix showed characteristics of free flux and good compression qualities very important for the excipients of direct compression in the market. Starch 1500® interfered in the disintegration time. The formulation with 6,35% of Starch 1500® proposed in this work obtained a highest proximity between the products in the Brazilian marketDownloads
Download data is not yet available.
Published
2008-04-24
How to Cite
Wanczinski, B. J., Felipe, D. F., C. Cardoso, M. L., & Cavalcanti, O. A. (2008). Development of AAS 500 mg tablets influenced by direct compression (CD) process. Acta Scientiarum. Health Sciences, 24, 649-655. https://doi.org/10.4025/actascihealthsci.v24i0.2479
Issue
Section
Health Sciences
DECLARATION OF ORIGINALITY AND COPYRIGHTS
I Declare that current article is original and has not been submitted for publication, in part or in whole, to any other national or international journal.
The copyrights belong exclusively to the authors. Published content is licensed under Creative Commons Attribution 4.0 (CC BY 4.0) guidelines, which allows sharing (copy and distribution of the material in any medium or format) and adaptation (remix, transform, and build upon the material) for any purpose, even commercially, under the terms of attribution.
Read this link for further information on how to use CC BY 4.0 properly.
5.png){kind=logo}
